XIDX
MERK
Market cap77mUSD
Nov 12, Last price
3,090.00IDR
Name
Merck Tbk PT
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Operating in Indonesia, PT Merck Tbk is a pharmaceutical company focused on the production and distribution of medicinal products. Its business operations are structured into three main divisions: Biopharma, Consumer Health, and an 'Others' segment. The company provides healthcare solutions addressing a broad spectrum of therapeutic areas, including conditions related to the cardiovascular system, metabolism, oncology, endocrinology, fertility, and neurodegenerative disorders, alongside general pharmaceutical offerings. Furthermore, PT Merck Tbk is actively involved in the discovery, development, production, and commercialization of both pharmaceutical and biological prescription drugs. These medicines target specific conditions such as colorectal and head and neck cancers, multiple sclerosis, infertility, growth hormone imbalances, diabetes, and various thyroid conditions like hyperthyroidism and hypothyroidism. Beyond its core pharmaceutical activities, the company also engages in property leasing and management. Established in 1970 and headquartered in East Jakarta, Indonesia, the company was originally known as PT Merck Indonesia Tbk before adopting its current name, PT Merck Tbk, in June 2002. It operates as a subsidiary of Merck Holding GmbH.
Related entities
Parent
E. Merck KG
Key people
Mei Ling Tang
President Commissioner · since 2017
Evie Yulin
President Director, Biopharma Director · since 2019
Bambang Nurcahyo
Finance Director · since 2009
Arryo Aritrixso Teguh Putranto Wachjuwidajat
Plant Director · since 2021
Melisa Sandrianti
Corporate Secretary · since 2018
Parulian Simanjuntak
Independent Commissioner · since 2003
Headquarters & legal address
JL.T.B.Simatupang No. 8 Pasar Rebo
Jakarta, JW 13760
ID
Jakarta, JW 13760
ID
Valuation
Title IDR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||